Josua Jordi

Obesity is a major burden for the billions of affected individuals since existing anti-obesity medical therapy is unsatisfactory both in terms of efficacy and safety. Josua Jordi and his team identified a set of small molecules with remarkable in vivo potency and selectivity in two vertebrate models. Within the Fellowship project, the team were able to solidify the promising candidate compounds using e.g. proof-of-concept studies in rats. In 2018 Josua Jordi and his co-founder Simon Breitler founded the UZH spinoff EraCal Therapeutics.

UZH Host Professor: Prof. Thomas Lutz

Start date: 09/2018

• Josua Jordi co-founded UZH Spin-off EraCal Therapeutics Ltd in 2018

• EraCal wins Venture Kick in 2019

• EraCal Therapeutics is among the top 10 in the “Health & Nutrition” vertical of the  »venture» business plan competition 2019

• EraCal won the MIT life science angels award in 2019

• Nestlé Health Science enters into Research Collaboration with EraCal Therapeutics

• New partnering deal with Novo Nordisk